Please try another search
For the three months ended 31 March 2019, Rexahn Pharmaceuticals, Inc. revenues was not reported. Net loss increased 13% to $2.3M. Higher net loss reflects Unrealized gain on fair value of warrant decrease of 55% to $1.5M (income), Other income decrease from $369K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.78 to -$0.62.
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -3.94 | -4.97 | -4.68 | -5 |
Net Income | -2.34 | -3.12 | -5.34 | -3.84 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Assets | 19.43 | 16.04 | 13.87 | 18.24 |
Total Liabilities | 3.49 | 5.48 | 7.46 | 6.81 |
Total Equity | 15.94 | 10.56 | 6.41 | 11.42 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -4.38 | -18.84 | -14.22 | -10.05 |
Cash From Investing Activities | -5.9 | 11.91 | 9.91 | 6.25 |
Cash From Financing Activities | 7.65 | 6.77 | 0 | 0 |
Net Change in Cash | -2.62 | -0.15 | -4.31 | -3.8 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review